Dermatology Review
facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2025
vol. 112
 
Share:
Send email
Share:
abstract:
Review article

The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis

Aleksandra Lesiak
1
,
Joanna Narbutt
1
,
Agnieszka B. Owczarczyk-Saczonek
2
,
Witold Owczarek
3
,
Maciej Pastuszczak
4
,
Adam Reich
5
,
Jacek C. Szepietowski
6
,
Irena Walecka
7
,
Julia M. Feldman
8

  1. Department of Dermatology, Pediatric Dermatology and Oncology, Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Poland
  2. Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Olsztyn, Poland
  3. Department of Dermatology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
  4. Department of Dermatology in Zabrze, Silesian Medical University in Katowice, Poland
  5. Department of Dermatology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
  6. Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland
  7. Department of Dermatology, CMKP/PIM MSWiA, Warsaw, Poland
  8. Sandoz Polska
Dermatol Rev/Przegl Dermatol 2025, 112, 93-103
DOI: https://doi.org/10.5114/dr.2025.153426
Online publish date: 2025/06/30
View full text Get citation
 
PlumX metrics:
According to European guidelines and the Diagnostic and Therapeutic Recommendations of the Polish Dermatological Society (Polskiego Towarzystwa Dermatologicznego, PTD), the therapeutic goal of the treatment of plaque psoriasis is currently full or almost full control of clinical symptoms. In patients with moderate-to-severe plaque psoriasis, systemic therapies are recommended, e.g. phototherapy and pharmacotherapy, including small-molecule synthetic drugs and biological drugs (both reference drugs and biosimilars). According to the PTD recommendations, biological treatment is indicated in patients with moderate-to-severe plaque psoriasis who do not respond to previous therapies. Due to its high efficacy and relatively low risk of adverse effects, biological therapy should be introduced as early as possible and continued for a long time, provided that the benefits outweigh the potential risk. The PTD recommendations do not specify the priority of choosing a specific biological drug, leaving this decision to the attending physician. The choice of a drug is influenced by various factors, both medical, related to the patient, and non-medical, including those related to the health care system. So far, 4 biosimilars have been registered for the treatment of plaque psoriasis, i.e. adalimumab, etanercept, infliximab and ustekinumab. The introduction of biosimilars to the market provides an opportunity to improve access to standard-of-care therapies.
keywords:

plaque psoriasis, biologics, biosimilars


Indeks osobowy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.